Presenting features of patients with CD38+AML and responses to culture with anti-CD38
| Pt . | Age (y) . | WBC (×109/L) . | FAB . | Karyotype . | CD38 Expression* (MFI) . | Cell Recovery After Culture With Anti-CD38† . |
|---|---|---|---|---|---|---|
| 1 | 11 | 98.4 | M2 | 46,XX,t(6;9)(p23;q34) [31] | 32.2 | 4% |
| 2 | 7 | 9.9 | M4 | 46,XX,inv(16)(p13.1q22) [10]/46,XX [12] | 82.3 | 36% |
| 47,XX,der(2)t(1;2)(q21;q35),t(5;12) | ||||||
| 3 | 14 | 26.2 | M1 | (p13;p13),del(8)(p21),+22 [19]/46,XX [1] | 17.7 | 8% |
| 4 | 7 | 88.8 | M2 | 46,XY [16] | 61.1 | 17% |
| 5 | 10 | 69.3 | M1 | 46,XY [40] | 94.6 | 63% |
| 6 | 15 | 86.2 | M5 | 48,XY,+8,+13 [4]/46,XY [19] | 57.3 | 23% |
| Pt . | Age (y) . | WBC (×109/L) . | FAB . | Karyotype . | CD38 Expression* (MFI) . | Cell Recovery After Culture With Anti-CD38† . |
|---|---|---|---|---|---|---|
| 1 | 11 | 98.4 | M2 | 46,XX,t(6;9)(p23;q34) [31] | 32.2 | 4% |
| 2 | 7 | 9.9 | M4 | 46,XX,inv(16)(p13.1q22) [10]/46,XX [12] | 82.3 | 36% |
| 47,XX,der(2)t(1;2)(q21;q35),t(5;12) | ||||||
| 3 | 14 | 26.2 | M1 | (p13;p13),del(8)(p21),+22 [19]/46,XX [1] | 17.7 | 8% |
| 4 | 7 | 88.8 | M2 | 46,XY [16] | 61.1 | 17% |
| 5 | 10 | 69.3 | M1 | 46,XY [40] | 94.6 | 63% |
| 6 | 15 | 86.2 | M5 | 48,XY,+8,+13 [4]/46,XY [19] | 57.3 | 23% |
WBC, white blood cell count; FAB, French-American-British classification; MFI, mean fluorescence intensity.
Percentage of cells with CD38 staining above the highest levels achievable with an isotype-matched control antibody was >90% in patients 2, 4, 5, and 6, 75% in patient 1 and 44% in patient 4. In the two latter patients, however, the whole cell population was shifted and no distinct CD38 negative subset was detectable.
Cell recovery after 7 days of culture on allogeneic bone marrow stroma in the presence of anti-CD38 (T16) is expressed as a percentage of cells recovered after parallel cultures with an isotype-matched nonreactive antibody. Results are the mean of 4 measurements.